Xue Qi Wang

Xue Qi Wang

Auto-generated profile, based on publicly available information

Xue Qi Wang

Department of Pathology University of British Columbia and BC Cancer Vancouver BC Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KAKarama Asleh
Karama Asleh
ALAna Lluch
Ana Lluch
AGAngela Goytain
Angela Goytain
CBCarlos Barrios
Carlos Barrios
XWXue Q. Wang
Xue Q. Wang
MMMiguel Martin
Miguel Martin
Purpose: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and capecitabine activation genes. We aimed to validate these findings on the larger phase III GEICAM/CIBOMA clinical trial. Experimental Design: Tumor tissues from patients with TNBC randomized to standard (neo)adjuvant chemotherapy followed by capecitabine versus observation were analyzed using a 164-gene NanoString custom nCounter codeset measuring mRNA expression. A prespecified statistical plan sought to verify the predictive capacity of PAM50 non-basal molecular subtype and tested the hypotheses that breast tumors with increased expression of (meta)genes for cytotoxic cells, mast cells, endothelial cells, PDL2, and 38 individual genes benefit from adjuvant capecitabine for distant recurrence-free survival (DRFS; primary endpoint) and overall survival. Results: Of the 876 women enrolled in the GEICAM/CIBOMA trial, 658 (75%) were evaluable for analysis (337 with capecitabine and 321 without). Of these cases, 553 (84%) were profiled as PAM50 basal-like whereas 105 (16%) were PAM50 non-basal. Non-basal subtype was the most significant predictor for capecitabine benefit [HRcapecitabine, 0.19; 95% confidence interval (CI), 0.07–0.54; P < 0.001] when compared with PAM50 basal-like (HRcapecitabine, 0.9; 95% CI, 0.63–1.28; P = 0.55; Pinteraction<0.001, adjusted P value = 0.01). Analysis of biological processes related to PAM50 non-basal subtype revealed its enrichment for mast cells, extracellular matrix, angiogenesis, and features of mesenchymal stem-like TNBC subtype. Conclusions: In this prespecified correlative analysis of the GEICAM/CIBOMA trial, PAM50 non-basal status identified patients with early-stage TNBC most likely to benefit from capecitabine.

21 January 2022 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
XWXue Qi Wang
Xue Qi Wang
AGAngela Goytain
Angela Goytain
BDBrendan C. Dickson
Brendan C. Dickson
TNTorsten O. Nielsen
Torsten O. Nielsen

1 March 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
XWXiu Q Wang
Xiu Q Wang
XWXue Q Wang
Xue Q Wang
AHAnika T Y W Hsu
Anika T Y W Hsu
AGAngela Goytain
Angela Goytain
TNTony L T Ng
Tony L T Ng
TNTorsten O. Nielsen
Torsten O. Nielsen
Histologic examination neither reliably distinguishes benign lipomas from atypical lipomatous tumor/well-differentiated liposarcoma, nor dedifferentiated liposarcoma from other pleomorphic sarcomas, entities with different prognoses and management. Molecular confirmation of pathognomonic 12q13-15 amplifications leading to MDM2 overexpression is a diagnostic gold standard. Currently the most commonly used assay for this purpose is fluorescence in situ hybridization (FISH), but this is labor intensive. This study assessed whether newer NanoString-based technology could allow for more rapid and cost-efficient diagnosis of liposarcomas on standard formalin-fixed tissues through gene expression. Leveraging large-scale transcriptome data from The Cancer Genome Atlas, 20 genes were identified, most from the 12q13-15 amplicon, that distinguish dedifferentiated liposarcoma from other sarcomas and can be measured within a single NanoString assay. Using 21 cases of histologically ambiguous low-grade adipocytic tumors with available MDM2 amplification status, a machine learning-based analytical pipeline was built that assigns a given sample as negative or positive for liposarcoma based on quantitative gene expression. The effectiveness of the assay was validated on an independent set of 100 sarcoma samples (including 40 incident prospective cases), where histologic examination was considered insufficient for clinical diagnosis. The NanoString assay had a 93% technical success rate, and an accuracy of 97.8% versus an MDM2 amplification FISH gold standard. NanoString had a considerably faster turnaround time and was cheaper than FISH.

23 August 2025 in Oncogene
Verified
Journal Article
Open access
PDF file
AWAmy Xueqi Wang
Amy Xueqi Wang
KJKevin B Jones
Kevin B Jones
TNTorsten O. Nielsen
Torsten O. Nielsen
The SS18::SSX oncogene is the driver of synovial sarcoma, an aggressive cancer presenting in young adults that has poor long-term outcomes. Over the past five years, significant progress has been made in understanding the molecular, genomic, and epigenetic mechanisms underlying synovial sarcoma. This review synthesizes recent advancements in synovial sarcoma, including diagnostic pathology, genomic profiling, SS18::SSX biology, epigenetic dysregulation, proteomics, targetable pathways and immunotherapy. Key findings include the identification of rare but instructive alternative gene fusions, the roles of PRC1 and of liquid-liquid phase separation in SS18::SSX-mediated oncogenesis, and the development of epigenetic and engineered T-cell therapies. These advances offer new hope for improved treatments and outcomes in synovial sarcoma patients, though challenges remain in overcoming resistance and ensuring equitable access to emerging therapies.

2 December 2025 in Nature Communications
Verified
Journal Article
Open access
LHLesley A. Hill
Lesley A. Hill
RSR. Wilder Scott
R. Wilder Scott
LMLauren A. Martin
Lauren A. Martin
MAMartin Arostegui
Martin Arostegui
GDGeorge Davenport
George Davenport
TUT. Michael Underhill
T. Michael Underhill
Synovial sarcoma (SyS) is an aggressive soft-tissue malignancy that is characterised by a pathognomonic t(X;18)(p11.2;q11.2) translocation, which produces the fusion oncogene named SS18::SSX. Despite recent advancements in our understanding of synovial sarcoma biology, the cell-of-origin remains undefined. A mesenchymal stromal cell (MSC) specific CreERT2 line was employed to express SS18::SSX in fibroblasts and related cell types, resulting in 100% penetrant synovial sarcoma development in mice, with a median latency period of 16.2 ± 2.8 weeks. Murine tumours exhibited high concordance with human synovial sarcoma subtypes at the histological and molecular levels. Genetic refinement of the cell-of-origin revealed that synovial sarcomas derive from a rare Hic1 + Pdgfra + Lgr5 + fibroblastic population. Furthermore, comparative transcriptomic analysis revealed the acquisition of a transformed phenotype initiated by the loss of a mature fibroblastic profile and subsequent unmasking of an epigenetically embedded embryonic MSC program. Adult and embryonic MSCs exhibited overlapping H2AK119ub and H3K4me3/ H3K27me3 (bivalent) histone marks, while SS18::SSX-mediated transformation culminated in the widespread loss of H3K27me3 at these genes and their consequent transcription. Collectively, these studies define a rare MSC context, conducive for SS18::SSX-mediated transformation, and demonstrate that SyS tumorigenesis involves the induction and maintenance of an embryoniclike MSC phenotype. Synovial sarcoma (SyS) is a malignant soft-tissue cancer that primarily affects adolescents or young adults and can arise in virtually any area of the body. The biologic behaviour of SyS can vary depending on a variety of factors, including histologic subtype, tumour size, and age at diagnosis. The 5-and 10-year survival rates have been estimated at approximately 60% and 50%, respectively 1,2. SySs typically arise in the deep soft tissues of the extremities 3 , although truncal 2 , as well as head and neck 3 sites are not uncommon.

25 November 2025
Verified
Other
Open access
KAKarama Asleh
Karama Asleh
ALAna Lluch
Ana Lluch
AGAngela Goytain
Angela Goytain
CBCarlos Barrios
Carlos Barrios
XWXue Q. Wang
Xue Q. Wang
MMMiguel Martin
Miguel Martin
Supplementary Data S1 shows exploratory analysis for the predictive capacity of the continuous expression of additional genes and metagenes included in the codeset. Supplementary Data S2 shows exploratory analysis for the prognostic capacity of the continuous expression of the selected genes and metagenes